



Universiteit
Leiden
The Netherlands

Immunodiagnosis of latent tuberculosis : new answers to an old question?

Franken, W.P.J.

Citation

Franken, W. P. J. (2009, June 10). *Immunodiagnosis of latent tuberculosis : new answers to an old question?*. Retrieved from <https://hdl.handle.net/1887/13840>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13840>

Note: To cite this publication please use the final published version (if applicable).

2

COMPARISON OF MANTOUX AND QUANTIFERON-TB GOLD TEST FOR DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN ARMY PERSONNEL

Willeke P.J. Franken¹, Joost F. Timmermans², Corine Prins¹,
Evert-Jan H.J. Slootman², Johan Dreverman², Hans Bruins², Jaap T. van Dissel¹,
and Sandra M. Arend¹

¹Department of Infectious Diseases, Leiden University Medical Center, The Netherlands

²Coordinating Center Expert Military Health Care of the Royal Dutch Armed Forces,
Hollandse Rading, The Netherlands

Clinical and Vaccine Immunology 2007;14:477-480

ABSTRACT

The tuberculin skin test (TST) was compared with QuantiFERON-TB Gold in-tube (QFT-GIT) in non-BCG vaccinated military personnel. Among subjects with a positive TST, 44.4% of recruits had a positive QFT-GIT compared with 11.5% after mission abroad, suggesting that most TST conversions in the latter group were caused by non-tuberculous mycobacteria.

Military personnel can be sent to high tuberculosis (TB) endemic countries and is therefore at higher risk of TB infection. Non-Bacillus Calmette-Guérin (BCG) vaccinated recruits entering the army are screened with the tuberculin skin test (TST) for detection of latent TB infection (LTBI), while BCG vaccinated recruits are screened using chest radiography. Screening is repeated following each return from a mission. If TST conversion ($TST \geq 10$ mm) is documented, prophylactic isoniazide (INH) is prescribed for 6 months.

Earlier studies using skin testing with sensitins from atypical mycobacteria such as *M. avium* or *M. scrofulaceum* indicated that about half of positive TST reactions in military personnel following return from mission were false-positive (3). New diagnostics, like QuantiFERON-TB Gold in-tube (QFT-GIT), have been developed using TB specific antigens ESAT-6, CFP-10 and TB7.7 (1;7;15). The advantages over the TST of these new assays are higher specificity, excluding false-positive results due to BCG or environmental mycobacteria, logistic simplicity and need of only one patient visit (9;14;15;17). In this study we used QFT-GIT for screening military personnel.

This prospective, cross-sectional observational study aimed to compare the TST with QFT-GIT in Dutch Armed Forces personnel. We aimed to recruit 750 employees who would be screened for TB infection six weeks after return from a military mission to a TB endemic area, and 150 recruits (new employees of the Dutch Armed Forces) as controls. In order to include a sufficient number of subjects with a positive TST among those who had been on mission, part of the subjects were randomly included on the day of TST administration and part was included on the day of TST reading if the TST result was > 0 mm. The Ethical Review Board of the Leiden University Medical Center approved the study protocol (Protocol number P04-027). All participants provided written informed consent. The TST and QFT-GIT were carried out as described previously (2). Analyses were performed using SPSS (Version 12.0.1; Apache Software Foundation). Differences between the study groups were evaluated using Pearson Chi-Square and Linear-by-Linear associations for univariate analyses. Results were considered significant if the p-value was < 0.05 . Multivariate analyses were performed using logistic regression. The agreement between TST and QFT-GIT was investigated using kappa statistics (16).

Between October 8th 2004 and February 3rd 2006, 909 subjects were included, of whom 171 were recruits and 674 had recently returned from mission, 34 were tested routinely for other reasons and of 30 participants these data are missing. Demographic characteristics are reported in Table 1.

TST results were available for 676/746 (90.6%) subjects. The TST was not performed in 163 subjects, 128 of whom were BCG vaccinated while 35 were known with previous TST conversion. Using ≥ 10 mm or ≥ 15 mm as TST cut-off, 139/676 (20.6%) and 51/676 (7.5%) subjects had a positive TST, respectively (table 2).

Analyzed by TST category, the distribution of TST results among subjects returning from mission and recruits was significantly different with an equally distributed higher percentage in each TST category >0 among subjects returning from mission (Table 1, $P<0.001$).

In univariate analysis, duration of the mission and birth in a high TB endemic region were predictive of a positive TST (data not shown). After adjusting for the day of inclusion in the study in a multivariate analysis, reported contact with the local population was the only parameter that was significantly associated with a positive TST.

Positive QFT-GIT results were obtained in 33/909 (3.6 %) of all participants. Among recruits, 5/171 results were positive (2.9 %), of whom two had previously been treated for TB. Of the remaining three, one was foreign born. Among subjects returning from mission, 28/738 (3.8 %) had a positive QFT-GIT result, which was not different from the percentage among recruits. Nine of those 28 (32.1%) reported past treatment of LTBI one to 14 years previously, compared to 1.6% (14/682) of the QFT-GIT negative participants. Three (10.7%) reported contact with smear-positive TB before the mission, compared to 6.7% (55/821) of the QFT-GIT negative group. As 12 of 28 (42.9%) positive QFT-GIT results were thus explained by the medical history, the actual risk of recent infection during mission was at most 16/725 (2.2%), or lower if LTBI had been acquired between enrollment in the Armed Forces and the mission. After adjusting for day of blood sampling in the multivariate analysis no parameters were associated with the QFT-GIT result (data not shown).

Results for both TST and QFT-GIT were available in 676 subjects, 20.6% of whom had a positive TST at cut off ≥ 10 mm and 3.1% of whom had a positive QFT-GIT result (Table 2). The overall agreement between TST and QFT-GIT was 82% ($\kappa=0.19$). When using 15 mm as the cut off, the agreement was 92% ($\kappa=0.24$, Table 2).

Table 1. Characteristics of the study population

	Recruits (N= 171)	After mission or other* (N= 738)	P-value
Gender	156/170 (91.8)	665/734 (90.6)	n.s.
Age, mean ± SD (y)	19.6 ± 2.8	30.3 ± 9.6	0.000
Country of Birth	158/171 (92.4)	692/737 (93.9)	n.s.
BCG vaccinated	15/171 (8.8)	93/738 (12.6)	n.s.
Visit Tropics	6/169 (3.6)	211/733 (28.8)	0.000
Timing of blood sample in relation to TST	146 (85.4)	384 (52.0)	0.000
	7 (4.1)	209 (28.3)	
TST at cutoff 10 mm	18 (10.5)	145 (19.6)	0.000
TST result, mean ± SD (mm)	9 (6.2)	130 (24.5)	0.000
TST result categorical, range (mm)	0.95 ± 3.9	3.4 ± 6.1	0.000
	134 (92.4)	362 (68.2)	0.000
	0 (0)	8 (1.5)	
	2 (1.4)	31 (5.8)	
	5 (3.4)	83 (15.6)	
	4 (2.8)	47 (8.9)	
QuantiFERON TB Gold (QFT-GIT) in tube result	5/171 (2.9)	28/738 (3.8)	n.s.
QFT-GIT result among TST positive subjects	4/9 (44.4)	15/130 (11.5)	0.000

Analysis based on available data; some data are missing due to incomplete questionnaires

Data are expressed as Number (%) unless indicated otherwise

BCG = Bacillus Calmette-Guérin

TST = Tuberculin Skin Test

QFT-GIT = QuantiFERON TB Gold in-tube

* N=34 medical personnel of Armed Forces eligible for routine screening

Table 2. Overall agreement between tuberculin skin test and QuantiFERON TB Gold in-tube test result

	TST < 10 mm	TST ≥ 10 mm	TST < 15 mm	TST ≥ 15 mm
QFT-GIT negative (N=655)	535 (81.7)	120 (18.3)	614 (93.7)	41 (6.3)
QFT-GIT positive (N=21)	2 (9.5)	19 (90.5)	11 (52.4)	10 (47.6)
All (N=676)	537 (79.4)	139 (20.6)	625 (92.5)	51 (7.5)
% Agreement	82.0		92.3	
κ	0.19		0.24	


TST = Tuberculin Skin Test
QFT-GIT = QuantiFERON TB Gold in-tube

Table 3. Distribution of concordant and discordant results for tuberculin skin test and QuantiFERON TB Gold in-tube

	Nr.	TST/QFT-GIT result (% within category)					concordant vs discordant P value
		concordant		discordant			
		neg/neg	pos/pos	pos/neg	neg/pos		
Gender	Male	79.4	2.6	17.6	0.3	0.535	
	Female	77.3	4.5	18.2	0.0		
Birth Country (TB incidence/y)	<10	79.7	2.6	17.4	0.3	0.297	
	10-49	100.0	0.0	0.0	0.0		
	50-99	50.0	0.0	50.0	0.0		
	100-199	40.0	20.0	40.0	0.0		
	≥ 200	60.0	20.0	20.0	0.0		
Tropics	No	80.0	2.4	17.1	0.4	0.363	
	Yes	76.6	4.3	19.1	0.0		
Contact TB	No	79.8	2.5	17.4	0.3	0.226	
	Yes	64.3	10.7	25.0	0.0		
Treated TB or LTBI	No	79.2	2.5	17.9	0.3	0.247	
	Yes	71.4	28.6	0.0	0.0		
History of positive TST	No	81.9	1.9	16.1	0.3	0.000	
	Yes	25.9	22.2	51.9	0.0		
Mission	No	38.9	11.1	50.0	0.0	0.000	
	Yes	77.1	2.6	19.9	0.4		
	Recrute	93.8	2.8	3.4	0.0		
Location of mission	Bosnia	44.4	5.6	50.0	0.0	0.000	
	Kyrgystan	76.2	0.0	23.8	0.0		
	Iraq	83.6	2.4	12.7	1.2		
	Afghanistan	77.7	2.6	19.7	0.0		
Duration mission (mo)	0-4	81.2	2.3	16.2	0.0	0.032	
	4-6	72.2	2.3	25.0	0.6		
	>6	56.3	12.5	31.3	0.0		

TB = Tuberculosis
 LTBI = Latent Tuberculosis Infection
 TST = Tuberculin Skin Test
 QFT-GIT = QuantiFERON TB Gold in-tube

Figure 1.



*Distribution of QuantiFERON TB Gold in-tube results in military personnel
Asterisk indicates two persons with TST = 0 mm and positive QFT-GIT result.*

Among subjects with a TST result ≥ 10 mm, 44.4 % (4/9) of the recruits had a positive QFT-GIT result, compared to 11.5 % (15/130) of participants returning from mission ($P<0.001$, Table 1). Among subjects with a TST result ≥ 15 mm, 25% of the recruits had concordant positive test results compared to 19% of subjects after mission ($P<0.001$). Discordance analysis (Table 3) showed that discordant results were more frequent among subjects returning from mission compared to recruits.

In this study, the low overall agreement between the TST and QFT-GIT of 82% ($\kappa = 0.19$) was explained by a high number of discordant TST positive, QFT-GIT negative results. At cut-off ≥ 10 mm, subjects returning from mission had a 4-fold higher rate of positive TST, whereas the rate of positive QFT-GIT was about 4-fold lower compared with new recruits. Notably, among participants with a positive TST 44.4 % of recruits had a positive QFT-GIT result compared with 11.5% of subjects returning from mission, confirming that most TST conversions after mission were false positive results caused by exposure to non-tuberculous mycobacteria (3). Assuming that most positive TST results among recruits truly indicated LTBI, the 11.5% positive QFT-GIT results among subjects returning from mission reflected $100/44.4 \times 11.5\%$, thus 25% with true LTBI. This would implicate that 75% of

observed positive TST results among these BCG unvaccinated subjects were probably false positive.

A limited number of studies used QFT-GIT in comparison with TST (2;4-6;8;12;13). It appeared that the agreement between the TST and QFT-GIT result was strongly dependent on the clinical-epidemiological setting, with the prevalence of TB and BCG vaccination status among the studied population as important determinants (5;8;12). Agreement was higher in studies of persons at significant risk of infection and lower values were found among BCG vaccinated subjects.

The U.S. Centers for Disease Control and Prevention recommend that QFT-G may be used instead of the TST in all circumstances in which the TST is currently used (11). U.K. guidelines issued by The National Institute for Health and Clinical Excellence (NICE) instead recommend a two-stage strategy of TST followed by an interferon gamma release assay to confirm a positive TST result (10). In the military setting of large scale screening and low *a priori* risk of LTBI, logistic problems could argue against the use of blood test for general screening. With a two-stage approach, however, it must be taken into account that the rate of TST reading can be low.

In conclusion, a positive TST was significantly less frequently associated with a positive QFT-GIT result among subjects returning from mission than among recruits. This suggests that false-positive TST results are frequent after mission. In this setting, QFT-GIT could guide more targeted treatment of individuals with actual LTBI and risk of TB disease.

Acknowledgements

The authors wish to thank all participants and the personnel of the Department of Preventive Health Care of the Ministry of Defense and the physicians of the Central Military Hospital in Utrecht for their co-operation with the study.

REFERENCE LIST

- (1) Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. *Lancet* 2000; 356(9235):1099-1104.
- (2) Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, Koster BF et al. Comparison of Two Interferon-Gamma Assays and Tuberculin Skin Test for Tracing TB Contacts. *Am J Respir Crit Care Med* (in press; Epub ahead of print as DOI: 10.1164/rccm.200608-1099OC).

- (3) Bruins J, Gribnau JH, Bwire R. Investigation into typical and atypical tuberculin sensitivity in the Royal Netherlands Army, resulting in a more rational indication for isoniazid prophylaxis. *Tuber Lung Dis* 1995; 76(6):540-544.
- (4) Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. *Respir Res* 2006; 7(1):77.
- (5) Dogra S, Narang P, Mendiratta DK, Chaturvedi P, Reingold AL, Colford JM, Jr. et al. Comparison of a whole blood interferon-gamma assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. *J Infect* 2006 (in press).
- (6) Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with *Mycobacterium tuberculosis*: a prospective study. *Lancet* 2006; 367(9519):1328-1334.
- (7) Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in *Mycobacterium tuberculosis* and virulent *Mycobacterium bovis* and for its absence in *Mycobacterium bovis* BCG. *Infect Immun* 1996; 64(1):16-22.
- (8) Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. *JAMA* 2005; 293(22):2756-2761.
- (9) Lalvani A, Richeldi L, Kunst H. Interferon gamma assays for tuberculosis. *Lancet Infect Dis* 2005; 5(6):322-324.
- (10) London, Royal College of Physicians. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. <http://www.nice.org.uk/CG033>. Date accessed 30-10-2006
- (11) Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting *Mycobacterium tuberculosis* infection, United States. *MMWR Recomm Rep* 2005; 54(RR-15):49-55.
- (12) Nakaoka H, Lawson L, Squire S.B, Coulter B, Ravn P, Brock I et al. Risk for tuberculosis among children. *Emerg Infect Dis* 2006; 12(9):1383-1388.
- (13) Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S et al. Serial Testing of Health Care Workers for Tuberculosis using Interferon-gamma Assay. *Am J Respir Crit Care Med* 2006.

- (14) Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. *Expert Rev Mol Diagn* 2006; 6(3):423-432.
- (15) Pai M, Riley LW, Colford JM, Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004; 4(12):761-776.
- (16) Petrie A, Sabin C. *Medical Statistics at a glance*. 2nd ed. Blackwell Publishing, 2006.
- (17) Rothel JS, Andersen P. Diagnosis of latent *Mycobacterium tuberculosis* infection: is the demise of the Mantoux test imminent? *Expert Rev Anti Infect Ther* 2005; 3(6):981-993.

